Latest news with #Cherny
Business Insider
15-07-2025
- Business
- Business Insider
Is Hims & Hers (HIMS) Stock a Buy After the Recent Pullback? Here's What Analysts Say
Hims & Hers Health (HIMS) stock has declined about 17% over the past month, mainly impacted by its fallout with Novo Nordisk (NVO). The Danish healthcare giant terminated its distribution agreement with Hims & Hers, accusing the telehealth company of illegally selling compounded versions of the weight loss drug Wegovy. Despite the recent selloff, HIMS stock is still up 98% year-to-date. Most Wall Street analysts don't see the correction in Hims & Hers stock as a buying opportunity and are currently cautious due to the ongoing challenges. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Analysts Are Cautious on Hims & Hers Stock Despite the termination of the partnership with Novo Nordisk, Hims & Hers bulls remain confident about the health and wellness platform's growth potential and opportunities in areas beyond GLP-1 drugs. Meanwhile, many analysts are cautious about HIMS stock due to legal risks and valuation concerns. Recently, Hims & Hers Health announced its planned entry into the Canadian market to offer affordable weight loss care. Reacting to the news, Leerink Partners analyst Michael Cherny reiterated a Hold rating on HIMS stock with a price target of $42. The 4-star analyst thinks that HIMS' entry into the Canadian market represents a logical and anticipated next step in its international expansion strategy, especially following the recent ZAVA acquisition. Cherny added that HIMS' move is clearly timed with the expected launch of generic semaglutide (active ingredient in Wegovy) in Canada, allowing HIMS to offer its personalized take/discounted pricing on a generic drug versus the 'ongoing push and pull of its compounded U.S. franchise.' Cherny contended that while the news doesn't come as a surprise, it reinforces HIMS' ability to leverage generically available products in new markets and diversify its revenue base. He views HIMS' expansion into Canada as a potential incremental revenue driver into 2026, 'though execution and uptake will be key to watch.' However, even with the foray into the Canadian market marking a potential contributor, Cherny remains neutral on HIMS stock as the uncertainty of the U.S. weight management franchise continues to create 'non-fundamental earnings volatility.' Meanwhile, analysts from Morgan Stanley and Truist are cautious on Hims & Hers stock due to legal risks. Recently, Truist analyst Jailendra Singh reaffirmed a Hold rating on HIMS stock with a price target of $45. Singh thinks that HIMS faces greater litigation risk after the termination of its short-lived partnership with Novo Nordisk. He noted Novo Nordisk's concerns around HIMS' 'illegal' mass compounding and 'deceptive' marketing practices. He added that while HIMS would argue that its compounding business is not violating any intellectual property (IP), Novo Nordisk could make a legal argument around other practices. A litigation, if there is one, could drag on for 18-24 months and could remain an overhang on HIMS stock, concluded Singh. Is HIMS Stock a Good Buy? Overall, Wall Street is sidelined on HIMS stock based on seven Holds, one Buy, and two Sell recommendations. The average HIMS stock price target of $41 indicates a downside risk of 14.4% from current levels.
Business Insider
12-07-2025
- Business
- Business Insider
Icon (ICLR) Gets a Buy from Leerink Partners
Leerink Partners analyst Michael Cherny reiterated a Buy rating on Icon on July 9. The company's shares closed yesterday at $150.52. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Cherny is a 4-star analyst with an average return of 4.7% and a 54.30% success rate. Cherny covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Cardinal Health, and CVS Health. In addition to Leerink Partners, Icon also received a Buy from Truist Financial's Jailendra Singh in a report issued on July 9. However, on June 25, Barclays maintained a Hold rating on Icon (NASDAQ: ICLR). ICLR market cap is currently $12.28B and has a P/E ratio of 16.38. Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ICLR in relation to earlier this year.
Yahoo
11-07-2025
- Business
- Yahoo
Leerink Partners Remains Bullish on GoodRx Holdings (GDRX)
GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 13 Best Healthcare Stocks to Buy Under $10. On June 13, Leerink Partners analyst Michael Cherny maintained a bullish stance on GoodRx Holdings, Inc. (NASDAQ:GDRX), giving the stock a Buy rating with a $7 price target. A pharmacist assisting elderly customers with their GoodRX codes at a local pharmacy. The analyst based the rating on the company's potential for growth and strategic expansion. He stated that GoodRx Holdings, Inc. (NASDAQ:GDRX) is leveraging its elaborate consumer market reach through the introduction of a subscription service for erectile dysfunction medications Sildenafil and Tadalafil at competitive price points. The analyst considers this move to be a promising expansion, aligning with the company's mission to slash out-of-pocket expenses for customers. Cherny further stated that GoodRx Holdings, Inc. (NASDAQ:GDRX) holds a significant opportunity to boost its market standing under new leadership, especially through its telehealth capabilities, which have historically been underutilized. Although he does not guarantee immediate success, the analyst believes that this strategic direction may result in a considerable broadening of GoodRx Holdings, Inc.'s (NASDAQ:GDRX) business beyond its core prescription transactions. The firm thus sees the company's expansion into subscription services as an innovative step that may differentiate it in the competitive digital health market. GoodRx Holdings, Inc. (NASDAQ:GDRX) offers a consumer-focused digital healthcare platform that provides free consumer access to convenient medical provider consultations through telehealth, reduced prices for brand and generic medications, and extensive healthcare research and information. While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
04-07-2025
- Politics
- New York Post
Dems plan for ‘Project 2029' met with skepticism as party continues to divide: Report
New York Times political correspondent Shane Goldmacher detailed the mixed opinions among political strategists on the Democratic Party's plan for Project 2029 — a ready-made agenda for the party's next presidential nominee. Goldmacher revealed on Monday that while many Democratic strategists are on board with the project's vision, some are skeptical that the agenda set forth could upset the left's 'interest-group Borg' and deepen the divide within the party. The creator of Project 2029, former Chair of the Arizona Democratic Party Andrei Cherny, is working on organizing Democratic thought leaders to ensure there is a set-in-stone agenda ready. 'The title is an unsubtle play on Project 2025, the independently produced right-wing agenda that Mr. Trump spent much of last year's campaign distancing himself from, and much of his first few months back in power executing,' Goldmacher noted in the piece. Cherny's plan takes more inspiration from the Heritage Foundation's Project 2025 than just its name. Similar to Project 2025, the goal of Project 2029 is to turn Cherny's publication, 'Democracy: A Journal of Ideas,' into a book — and rally the party's presidential candidates behind those ideas during the 2028 primary election season. 3 CEO of Aspiration Andrei Cherny attends a special Washington, DC screening of 'An Inconvenient Sequel: Truth to Power' at The Newseum on July 19, 2017 in Washington, DC. Getty Images for Paramount Pictures 'The undertaking, which has not previously been reported, strikes at the heart of a raging debate consuming Democratic lawmakers, strategists and policymakers: whether the root of the party's problems is its ideas or its difficulty in persuading people to embrace them,' Goldmacher stated. According to Celinda Lake, a prominent Democratic pollster quoted in the story, the party 'didn't lack policies,' but rather 'lacked a functioning narrative to communicate those policies.' She criticized the Democratic Party for offering voters 'agencies and acronyms and statistics' rather than presenting a clear story about 'what we're going to fight for.' On the other hand, some Democrats contend that the party has been faltering due to stale ideas that fail to inspire voters to get behind them. 3 Mallory McMorrow, Michigan State Senator, makes remarks on Project 2025 at the 2024 Democratic National Convention in Chicago, Illinois, USA, at the United Center on Monday, August 19, 2024. Ron Sachs – CNP for NY Post Neera Tanden, CEO of the Center for American Progress and advisor to Project 2029, argued that liberals 'underestimate the power of Trump's ideas' and that the focus has been his personality. 'We get wrapped up in his personality. But he puts forward an idea like 'No tax on tips,' and that's an important signifier that he is championing working-class people,' Tanden told the New York Times. Cherny's plan to assemble 'the Avengers of public policy' — a coalition of Democrats aiming to set the agenda for their party's next presidential candidate — did not sit well with some who believe that coalitions are to blame for the party's current predicament. 3 A scoreboard displays 'DNC 2024' ahead of the Democratic National Convention (DNC) at the United Center on August 16, 2024 in Chicago, Illinois. The United Center will host the DNC, which is officially scheduled to kick off on Monday, August 19 and run through Thursday, August 22. Getty Images 'Developing policies by checking every coalitional box is how we got in this mess in the first place,' stated Adam Jentleson in the piece, the former chief of staff for Sen. John Fetterman, D-Pa. 'There is no way to propose the kind of policies the Democratic Party needs to adopt without pissing off some part of the interest-group Borg. And if you're too afraid to do that, you don't have what it takes to steer the party in the right direction.' Even though Democrats were successful in rallying their base against Project 2025, Michael Tomasky, editor of The New Republic, claimed that those efforts will not have a negative effect on Project 2029 because — unlike the Heritage Foundation — their 'ideas aren't radical or extreme.' Tomasky stated that he hoped the project would help rejuvenate the public's view of the Democratic Party among the less fortunate.
Yahoo
25-06-2025
- Business
- Yahoo
Leerink Partners Reiterates a Hold Rating on Walgreens Boots Alliance (WBA)
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) is one of the . On April 10, analyst Michael Cherny of Leerink Partners reiterated a Hold rating on Walgreens Boots Alliance, Inc. (NASDAQ:WBA), retaining the price target of $11.50. The analyst based the rating on the company's strategic developments and recent performance. He stated that the company's pharmacy segment underwent significant growth with a rise in comparable prescriptions, especially in the back of the store. However, the store's front experienced challenges, including a fall in the sale of discretionary items. This affected overall retail sales. A pharmacist discussing the health benefits of a prescription medication with a customer. The analyst also reasoned that while Walgreens Boots Alliance, Inc. (NASDAQ:WBA) is showing positive momentum in its international operations, they were offset by a rise in investments in technology and payroll. The US Healthcare segment, however, exhibited improved profitability, which Cherny attributed to contributions from Shields and VillageMD. Walgreens Boots Alliance, Inc. (NASDAQ:WBA) also announced a definitive agreement to be acquired by Sycamore Partners in March in a transaction valued at up to $23.7 billion. Walgreens Boots Alliance, Inc. (NASDAQ:WBA) is an American multinational company providing retail, pharmacy, and healthcare services. The company has approximately 12,500 locations across the US, Europe, and Latin America. Its brand portfolio includes well-known brands such as Walgreens, Boots, Duane Reade, and Benavides. While we acknowledge the potential of WBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
